- Management of psoriatic disease with anti IL-17 and anti-IL-23 monoclonal antibodies2022 | Faculty of Medicine in Hradec Králové
- Guselkumab - the first selective IL-23 inhibitor for the treatment of psoriatic arthritis2023 | First Faculty of Medicine
- Risankizumab in first-line treatment of psoriasis2022 | Faculty of Medicine in Pilsen
- Guselkumab - první inhibitor IL-23 v léčbě psoriázy2019 | Third Faculty of Medicine
- Risankizumab in treatment of psoriatic arthritis2023 | First Faculty of Medicine
- p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+T-cells2017 | Second Faculty of Medicine
- Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study2022 | Third Faculty of Medicine
- Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study2021 | Third Faculty of Medicine
- Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology2006 | First Faculty of Medicine
- CD40 stimulation induces IL-23 mediated cell independent intestinal inflammationPublication without faculty affiliation
- Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathologyPublication without faculty affiliation
- Photoprotection in drug-induced photosensitivity2020 | Third Faculty of Medicine
- p19-targeting ILP protein blockers of IL-23/Th-17 pro-inflammatory axis displayed on engineered bacteria of food origin2018 | Faculty of Science
- Current Approach to Modern Treatment of Psoriasis - Updated Guidelines of ČDS JEP for Targeted Treatment of Severe Chronic Psoriasis2019 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen
- Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities2022 | First Faculty of Medicine, Second Faculty of Medicine
- Ustekinumab in systemic treatment of psoriasis2009 | First Faculty of Medicine
- Modulation of IL-12/IL-23 signaling pathways by ustekinumab alleviates inflammation in Crohn's disease patients2018 | Faculty of Medicine in Hradec Králové
- Léčba risankizumabem u dvou pacientů s těžkou psoriázou po switchi z jiné biologické terapie2021 | Third Faculty of Medicine
- Efficacy of biological treatment of moderate to severe psoriasis - analysis from the BIOREP Registry2021 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (Clinical trial IMMerge)2020 | Faculty of Medicine in Pilsen
- Úspěšná léčba psoriázy risankizumabem u HIV pozitivního pacienta2022 | First Faculty of Medicine, Second Faculty of Medicine
- Nová biologická léčba psoriázy: risankizumab - první klinické zkušenosti2020 | Third Faculty of Medicine
- Psoriasis treatment goals - time for a change?2023 | Faculty of Medicine in Pilsen
- Inhibition of interleukins 12 and 23 - experience of plaque psoriasis therapy by ustekinumab2013 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Th17 lymphocytes in anti-infectious immunity: What have we learnt from the studies in primary immunodeficiencies?2010 | Second Faculty of Medicine
- Léčba psoriázy2015 | Third Faculty of Medicine
- Expansion of T helper type 17 lymphocytes in patients with chronic granulomatous disease2011 | Second Faculty of Medicine
- Recommendations of the Czech Society of Rheumatology for the treatment of psoriatic arthritis2023 | First Faculty of Medicine
- Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha2021 | Third Faculty of Medicine
- Zkušenosti s risankizumabem v léčbě středně těžké až těžké psoriázy v běžné klinické praxi2021 | Third Faculty of Medicine